for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Healios KK

4593.T

Latest Trade

1,260.00JPY

Change

12.00(+0.96%)

Volume

159,000

Today's Range

1,227.00

 - 

1,270.00

52 Week Range

1,207.00

 - 

2,180.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1,248.00
Open
1,244.00
Volume
159,000
3M AVG Volume
3.36
Today's High
1,270.00
Today's Low
1,227.00
52 Week High
2,180.00
52 Week Low
1,207.00
Shares Out (MIL)
51.23
Market Cap (MIL)
63,938.16
Forward P/E
-15.99
Dividend (Yield %)
--

Next Event

Q3 2019 Healios KK Earnings Release

Latest Developments

More

Healios KK to set up unit Organoid Neogenesis Laboratory

Healios KK and NEI enter into collaborative research and development agreement

Athersys And Healios Extend By One Month The Period To Complete Collaboration Expansion Agreements

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Healios KK

HEALIOS K.K. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The Company has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.

Industry

Biotechnology & Drugs

Contact Info

11F, Seiroka Tower, 8-1, Akashi-cho

+81.3.57778308

https://www.healios.co.jp/

Executive Leadership

Tadanao Kagimoto

President, Representative Director

Kyoko Takahashi

Executive Officer, Director of Finance & Accounting

Masanori Sawada

Managing Director, Director of Business Development

Yoshinari Matsuda

Executive Director

Ken Ishikawa

Executive Officer, Director

Key Stats

1.80 mean rating - 5 analysts
Sell
Hold
Buy
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
6.71
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
28.51
LT Debt To Equity (MRQ)
27.28
Return on Investment (TTM)
-27.46
Return on Equity (TTM)
-23.65

Latest News

BRIEF-Healios to set up U.S.-based unit Healios N.A.

* Says it will set up a wholly owned unit Healios N.A. Inc, which will be engaged in development of medical supplies in March

BRIEF-Healios announces exercise of options

* Says 12,000 units of its tenth series options were exercised to 1.2 million shares of its common stock from Oct. 2 to Oct. 30

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up